Eli Lilly and Co

Eli Lilly and Co (LLY) Stock Analysis

$1,166.510

-15.865 (-1.36%)At close

Loading chart…
High
1,193.300
Open
1,190.700
VWAP
1,172.74
Volume
1.84M
Mkt Cap
863.96B
Low
1,158.405
Amount
2.16B
EV/EBITDA, TTM
19.09

Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries.

www.lilly.com

AI analysis of Eli Lilly and Co (LLY)

Buy

Eli Lilly is a good buy right now due to its current price of $1179.27, a strong year-to-date change of +9.16%, and a forward P/E ratio of 24.39, which suggests growth potential. The main risk is the high debt to equity ratio of 162.07%, indicating potential financial strain.

Analyst Ratings (22)

Buy
13 Buy
8 Hold
1 Sell
Current: 1,166.51
Low
950.00
Average
—
High
—

BofA

2026-10-09

Price Target

—

Buy

Cantor Fitzgerald

2026-10-08

Price Target

—

Overweight

Morgan Stanley

2026-10-07

Price Target

—

Overweight

JPMorgan

2026-09-28

Price Target

—

Overweight

Guggenheim

2026-09-18

Price Target

—

Buy

Valuation Metrics

The current forward P/E ratio for Eli Lilly and Co (LLY) is 24.39, compared to its 5-year average forward P/E of 40.89.

Forward P/E

Undervalued
5Y Average P/E
40.89
Current P/E
24.39
Overvalued
51.90
Undervalued
29.88

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
30.14
Current EV/EBITDA
19.09
Overvalued
37.70
Undervalued
22.58

Forward P/S

Fair
5Y Average P/S
11.55
Current P/S
10.29
Overvalued
13.87
Undervalued
9.24

Alphio AI Price Scenarios for LLY

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%LLY

$1,138.36

Scenario price

B

Base

Base · 50%LLY

$934.36

Scenario price

B

Bear

Bear · 25%LLY

$711.76

Scenario price

Whales holding LLY

C

Corient Private Wealth LP

+ HoldingLLY

+52.24%

3M Return

P

PKO Towarzystwo Funduszy Inwestycyjnych SA

+ HoldingLLY

+12.82%

3M Return

S

Sanlam Investment Management (Pty) Ltd.

+ HoldingLLY

+12.71%

3M Return

C

Compound Global Advisors, LLC

+ HoldingLLY

+12.19%

3M Return

D

Diversify Wealth Management, LLC

+ HoldingLLY

+11.82%

3M Return

C

Caixa Econômica Federal

+ HoldingLLY

+11.46%

3M Return

Events Timeline

2026-10-13 (ET)

07:30:00

Prelude Therapeutics Announces Clinical Trial Collaboration with Eli Lilly

2026-10-09 (ET)

07:00:00

Eli Lilly Announces New Data from TOGETHER-PsO Trial

2026-10-05 (ET)

08:30:00

Gate Bioscience Expands Collaboration with Eli Lilly, Potential Value Exceeds $870M

2026-10-02 (ET)

15:30:00

Eli Lilly's Jaypirca Approved by FDA for Chronic Lymphocytic Leukemia

News

LLY FAQ — answered by Alphio AI

Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Eli Lilly is a good buy right now due to its current price of $1179.27, a strong year-to-date change of +9.16%, and a forward P/E ratio of 24.39, which suggests growth potential. The main risk is the high debt to equity ratio of 162.07%, indicating potential financial strain.

22 analysts cover LLY: 13 rate it Buy, 8 Hold and 1 Sell. The average price target is 1,192.

Community

More ↗
RektUrchin17 hr. ago

Rotation into defensive sectors like healthcare this morning. Here's $LLY, which continues to set up constructively.

Show more
0xLunarbazaar9/21/2026

$SPY $DKNG $LLY $PSKY $VLVLY 1) In a post on Truth Social, President Trump states: "...I will be announcing, in the near future, the AI 'Czar' - Only High I.Q. individuals need apply! AI is the next Industrial Revolution, or Internet, but will be even larger and more impactful, possibly as much as 25% of our Country's GDP. We are leading China, and the rest of the World, and I intend to keep it that way!" 2) DraftKings (DKNG) puts customer betting records into a machine learning model to find out who is most likely to make losing bets, Alex Klavens, Walt Bogdanich and Jenny Vrentas of New York Times report. The company uses data science to target losing gamblers with promotions that encourage more betting, six former employees told the Times. 3) Some emerging scientific research points to an increased risk for GLP-1 patients to develop nonarteritic anterior ischemic optic neuropathy, or vision loss, Alex Janin of Wall Street Journal reports. GLP-1 developers Novo Nordisk (NVO) and Eli Lilly (LLY) face lawsuits from patients claiming the medications caused NAION, the Journal adds. 4) Paramount (PSKY) and states looking to block its acquisition of Warner Bros. (WBD) could settle as soon as this week, Jody Godoy of Reuters reports, citing sources familiar with the matter. A commitment on the number of movie releases is among the terms of the settlement, the sources added. 5) The Board of Directors of Volvo Cars (VLVLY) has appointed Klaus Zellmer as President and Chief Executive Officer. Klaus Zellmer will assume the position no later than 1 October 2027. Hakan Samuelsson will, together with the Board, ensure a seamless transition. Klaus Zellmer most recently served Chairman of the Board of Management and CEO of Skoda Auto, a Volkswagen (VWAGY) company.

Show more
0xLunarbazaar9/19/2026

$LLY $NVO Lilly and Novo face lawsuits over GLP-1 vision loss risk, WSJ says. Some emerging scientific research points to an increased risk for GLP-1 patients of developing nonarteritic anterior ischemic optic neuropathy, or vision loss, Alex Janin of the Wall Street Journal reports. GLP-1 developers Novo Nordisk (NVO) and Eli Lilly (LLY) face lawsuits from patients claiming the medications caused NAION, the Journal adds. Evidence of the vision loss risk is mixed and not clear enough to say whether or how the drugs cause the condition, doctors and researchers said, according to the Journal.

Show more
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started